Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ABILIFY ASIMTUFII
Published 2025-12-23 · Last reviewed 2025-12-30 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Abilify Asimtufii is a long-acting injectable aripiprazole formulation designed for dosing every 2 months (q8wk).
It is used for schizophrenia and for maintenance monotherapy treatment of bipolar I disorder. It is often selected when adherence challenges or frequent relapse make a scheduled injection visit preferable to daily pills.
Aripiprazole is a D2/D3 partial agonist antipsychotic with a comparatively lower prolactin burden than many SGAs, but Akathisia/restlessness and insomnia can limit tolerability.
Label describes sustained plasma concentrations over 2 months with a broad Tmax range and a mean apparent terminal half-life after a single dose of ~21 days.
For interval comparisons across depot options, see the LAI Navigator and the compare view.
Asimtufii extends aripiprazole depot dosing to a q8-week schedule. It can reduce visit burden but also slows "steerability" when adverse effects or underdosing emerge. Practical constraints include initiation logistics (oral overlap vs 1-day regimen), missed-dose protocols, and early identification of akathisia/activation symptoms.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Aripiprazole stabilizes dopamine and serotonin signaling through partial agonism and selective antagonism.
Dopamine D2/D3 partial agonism can attenuate hyperdopaminergic pathways linked to positive symptoms while supporting cortical dopaminergic tone relevant to negative symptoms. Serotonin 5-HT1A partial agonism and 5-HT2A antagonism contribute to mood-stabilizing effects.